The Journal of Experimental Medicine
Torrey Pines Biolabs
  Home | Help | Feedback | Subscriptions | Archive | Search | Table of Contents

Published online 10 February 2003 doi:10.1084/jem.20021293
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Citation Map
Services
Right arrow Email this article
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new content in the JEM
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Mauri, C.
Right arrow Articles by Londei, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mauri, C.
Right arrow Articles by Londei, M.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?
© Rockefeller University Press, 0022-1007/2003/2/489 $5.00
The Journal of Experimental Medicine, Volume 197, Number 4, 489-501

Prevention of Arthritis by Interleukin 10–producing B Cells

Claudia Mauri1, David Gray2, Naseem Mushtaq1 and Marco Londei1

1 The Kennedy Institute of Rheumatology Division, Faculty of Medicine, Imperial College of Science Technology and Medicine, London W6 8 LH, United Kingdom
2 Institute of Cell Animal and Population Biology, University of Edinburgh, Ashworth Laboratories, Edinburgh EH93JT, United Kingdom

Address correspondence to C. Mauri at her present address, Centre for Rheumatology Research, The Windeyer Institute of Medical Science, 46 Cleveland Street, London W1T 4JF. Phone: 44-207-679-9670; Fax: 44-207-679-9143; E-mail: c.mauri{at}ucl.ac.uk; or M. Londei at his present address, Institute of Child Health, University College London, 30 Guilford Street, London WC1N 1EH, UK. Phone: 44-207-905-2182; Fax: 44-207-905-2316; E-mail: m.londei{at}ich.ucl.ac.uk

In this study we have shown that activation of arthritogenic splenocytes with antigen and agonistic anti-CD40 gives raise to a B cell population that produce high levels of interleukin (IL)-10 and low levels of interferon (IFN)-{gamma}. Transfer of these B cells into DBA/1-TcR-ß-Tg mice, immunized with bovine collagen (CII) emulsified in complete Freund's adjuvant inhibited T helper type 1 differentiation, prevented arthritis development, and was also effective in ameliorating established disease. IL-10 is essential for the regulatory function of this subset of B cells, as the B cells population isolated from IL-10 knockout mice failed to mediate this protective function. Furthermore, B cells isolated from arthritogenic splenocytes treated in vitro with anti–IL-10/anti–IL-10R were unable to protect recipient mice from developing arthritis. Our results suggest a new role of a subset of B cells in controlling T cell differentiation and autoimmune disorders.

Key Words: autoimmunity • immunoregulation • B cells • interleukin 10 • CD40


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:



  Home | Help | Feedback | Subscriptions | Archive | Search
TABLE OF CONTENTS